» Articles » PMID: 34983622

Estimating the Frequency of Causal Genetic Variants in Foetuses with Congenital Heart Defects: a Chinese Cohort Study

Overview
Publisher Biomed Central
Specialty General Medicine
Date 2022 Jan 5
PMID 34983622
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The belief that genetics plays a major role in the pathogenesis of congenital heart defects (CHD) has grown popular among clinicians. Although some studies have focused on the genetic testing of foetuses with CHD in China, the genotype-phenotype relationship has not yet been fully established, and hotspot copy number variations (CNVs) related to CHD in the Chinese population are still unclear. This cohort study aimed to assess the prevalence of chromosomal abnormalities in Chinese foetuses with different types of CHD.

Results: In a cohort of 200 foetuses, chromosomal abnormalities were detected in 49 (24.5%) after a prenatal chromosome microarray analysis (CMA), including 23 foetuses (11.5%) with aneuploidies and 26 (13.0%) with clinically significant CNVs. The additional diagnostic yield following whole exome sequencing (WES) was 11.5% (6/52). The incidence of total chromosomal abnormality in the non-isolated CHD group (31.8%) was higher than that in the isolated CHD group (20.9%), mainly because the incidence of aneuploidy was significantly increased when CHD was combined with extracardiac structural abnormalities or soft markers. The chromosomal abnormality rate of the complex CHD group was higher than that of the simple CHD group; however, the difference was not statistically significant (31.8% vs. 23.6%, P = 0.398). The most common CNV detected in CHD foetuses was the 22q11.2 deletion, followed by deletions of 5p15.33p15.31, deletions of 15q13.2q13.3, deletions of 11q24.2q25, deletions of 17p13.3p13.2, and duplications of 17q12.

Conclusions: CMA is the recommended initial examination for cases of CHD in prenatal settings, for both simple heart defects and isolated heart defects. For cases with negative CMA results, the follow-up application of WES will offer a considerable proportion of additional detection of clinical significance.

Citing Articles

Simultaneous CNV-seq and WES: An effective strategy for molecular diagnosis of unexplained fetal structural anomalies.

Zhang H, He X, Wang Y, Li C, Jiang H, Hou S Heliyon. 2024; 10(20):e39392.

PMID: 39502218 PMC: 11535759. DOI: 10.1016/j.heliyon.2024.e39392.


Risk of venous thromboembolism in patients with congenital heart disease: a nationwide, register-based, case-control study.

Cuszynska-Kruk D, Fedchenko M, Giang K, Dellborg M, Eriksson P, Hansson P Eur Heart J Open. 2024; 4(6):oeae089.

PMID: 39493573 PMC: 11529300. DOI: 10.1093/ehjopen/oeae089.


Prenatal diagnosis in fetal right aortic arch using chromosomal microarray analysis and whole exome sequencing: a Chinese single-center retrospective study.

Zhang L, Huang R, Zhou H, Lin X, Guo F, Jing X Mol Cytogenet. 2024; 17(1):22.

PMID: 39334424 PMC: 11438370. DOI: 10.1186/s13039-024-00691-3.


Genomic insights into prenatal diagnosis of congenital heart defects: value of CNV-seq and WES in clinical practice.

Sun S, Ji Y, Shao D, Xu Y, Yang X, Sun L Front Genet. 2024; 15:1448383.

PMID: 39205944 PMC: 11349688. DOI: 10.3389/fgene.2024.1448383.


Prenatal chromosomal microarray analysis in a large Chinese cohort of fetuses with congenital heart defects: a single center study.

Lu Q, Luo L, Zeng B, Luo H, Wang X, Qiu L Orphanet J Rare Dis. 2024; 19(1):307.

PMID: 39175064 PMC: 11342572. DOI: 10.1186/s13023-024-03317-4.


References
1.
Hartman R, Rasmussen S, Botto L, Riehle-Colarusso T, Martin C, Cragan J . The contribution of chromosomal abnormalities to congenital heart defects: a population-based study. Pediatr Cardiol. 2011; 32(8):1147-57. DOI: 10.1007/s00246-011-0034-5. View

2.
Qiao F, Wang Y, Zhang C, Zhou R, Wu Y, Wang C . Comprehensive evaluation of genetic variants using chromosomal microarray analysis and exome sequencing in fetuses with congenital heart defect. Ultrasound Obstet Gynecol. 2020; 58(3):377-387. DOI: 10.1002/uog.23532. View

3.
Cowan J, Ware S . Genetics and genetic testing in congenital heart disease. Clin Perinatol. 2015; 42(2):373-93, ix. DOI: 10.1016/j.clp.2015.02.009. View

4.
Dai Y, Liang S, Dong X, Zhao Y, Ren H, Guan Y . Whole exome sequencing identified a novel DAG1 mutation in a patient with rare, mild and late age of onset muscular dystrophy-dystroglycanopathy. J Cell Mol Med. 2018; 23(2):811-818. PMC: 6349151. DOI: 10.1111/jcmm.13979. View

5.
Dorn C, Grunert M, Sperling S . Application of high-throughput sequencing for studying genomic variations in congenital heart disease. Brief Funct Genomics. 2013; 13(1):51-65. DOI: 10.1093/bfgp/elt040. View